OTC Watch

All stocks / PTPI

Petros Pharmaceuticals, Inc. PTPI

Petros Pharmaceuticals (PTPI): a late 10-K notice in March 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated floatLate filing Pink LimitedNew York, USA
Live quote on OTC Markets

Market listing

Full name
PETROS PHARMACEUTICALS INC
Market tier
OTC Pink Limited
Trading status
Active
Last trade
09:30:39
Website
petrospharma.com
Source: Stockwatch, 2026-11-17

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net income
$1,913,595
What it means

It earned more than it spent

Steady

After all costs, the company kept $1.9 million as profit in the year.

The report says
Cash and cash equivalents
$5,136,722
Net cash used in operating activities
($6,734,707)
What it means

The cash could run out soon

Under strain

It had $5.1 million in the bank and used about $561,226 a month. At that pace the money lasts about 9 months unless it borrows or sells more shares.

The report says
Total assets
$5,163,598
Total liabilities
$2,292,744
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $5.2 million. Its debts and unpaid bills add up to $2.3 million. That is about $0.44 owed for every $1 owned.

What this adds up to

1 of 3 checks show strain. The cash could run out soon. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-08-15

Estimated float about 28,043,157 shares as of 2026-08-15: 42,372,260 outstanding minus 14,329,103 held by 4 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Late filing2026-03-31

Filed NT 10-K on 2026-03-31: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Shares outstanding

Source: SEC filings
2025-09-30
42.3M
2025-11-12
42.4M
2025-12-31
42.3M
2026-03-31
42.4M
2026-04-15
42.4M
2026-05-12
42.4M
2026-06-30
42.4M
2026-08-15
42.4M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-09-30 8-KFORM 8-K
2026-08-13 10-Q10-Q
2026-06-25 3OWNERSHIP DOCUMENT
2026-06-18 8-KFORM 8-K
2026-06-08 4OWNERSHIP DOCUMENT
2026-06-05 8-KFORM 8-K
2026-06-05 4OWNERSHIP DOCUMENT
2026-06-05 4OWNERSHIP DOCUMENT
2026-06-05 4OWNERSHIP DOCUMENT
2026-05-13 10-Q10-Q
2026-04-15 10-K10-K
2026-03-31 NT 10-KNT 10-K

Common questions about PTPI

Does PTPI file reports with the SEC?

Yes. Petros Pharmaceuticals files with the SEC under company number 0001815903. The most recent filing we hold is a 8-K dated 2026-09-30.

Source record

How many PTPI shares are outstanding?

42,372,260 shares as of 2026-08-15, as reported to the SEC.

Source record

Has PTPI filed reports late?

Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-K on 2026-03-31. A notice means a report was not ready on time; check whether the report followed.

Source record

Who runs Petros Pharmaceuticals?

Officers named in its insider filings: Fady Boctor (See Remarks) and Robert Weinstein (Chief Accounting Officer).

Source record

Is Petros Pharmaceuticals making money?

After all costs, the company kept $1.9 million as profit in the year. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record